The Epstein-Barr virus (EBV) isthe causative agentof mononucleosis but can also induce transformation of infected cells leading to lymphoma (B cells) and carcinoma(epithelial cells). EBV uses G protein-coupled receptor (GPCR) signaling and trafficking to escape the host immune response and to induce cellulartransformation.Both virus encoded and host GPCRs, BILF1 and EBI2,may represent targetsfor therapeutic intervention tointerfere withtumorigenesis and to limit viral immune escape[62, 63]. We would like to take advantages of a novelstrategyto target GPCRs, which are small stable single-domain camelid antibody fragmentscalled Nanobodies[64-66]. Besides the direct use of soluble Nanobodies to inhibit the activity ofBILF1 or EBI2 in viral replication and tumorogenesis, we propose to fuse the generated Nanobodies to human immunoglobulin Fc domains to create chimeric (camelid-human) antibodies.Such an approach may openupnew therapeutic avenues to treat viral infections or cancers in which GPCRs play an important role.
|Acronym||NEXTIMMUNE (Nathan Reynders)|
|Effective start/end date||1/01/17 → 31/12/20|
- FNR - Fonds National de la Recherche: €169,500.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.